Researchers use CareDx solutions to monitor first successful heart xenotransplantation
Click Here to Manage Email Alerts
CareDx Inc. announced its non-invasive organ transplant surveillance solutions were used to monitor postoperative graft health in the first successful heart xenotransplantation.
According to the press release, surgeons from the University of Maryland School of Medicine (UMSOM) are using versions of two Care-Dx surveillance solutions to monitor the genetically modified pig heart they transplanted into a patient on Jan. 7, 2022.
“We are taking every precaution to ensure the optimal care of the world’s first successful transplantation of a genetically modified pig heart, including using CareDx’s non-invasive multimodality surveillance solutions to help monitor graft health,” Bartley P. Griffith, MD, professor of surgery and clinical director of the Cardiac Xenotransplant Program at UMSOM, said in the press release.
Using gene expression profiling, researchers are measuring immune quiescence and donor-derived cell-free DNA to identify graft injury in the patient.
“As an innovator in organ transplant surveillance, CareDx is proud to be working with UMSOM on this landmark case which represents a groundbreaking moment in the history of transplantation,” Reg Seeto, CEO and president of CareDx, said in the release. “It’s incredibly rewarding to apply our years of experience and dedication to the transplant community by offering the world’s first biomarker surveillance solution for xenotransplantation. We look forward to continuing to work closely with surgeons at UMSOM and the extended care team at the University of Maryland Medical Center to help ensure long-term success for this patient.”
Click Here to Manage Email Alerts